nach oben

Erschienen in:

10.11.2020 | COVID-19 | STATE OF THE ART REVIEW Zur Zeit gratis

ACE2: The Major Cell Entry Receptor for SARS-CoV-2

verfasst von: Filippo Scialo, Aurora Daniele, Felice Amato, Lucio Pastore, Maria Gabriella Matera, Mario Cazzola, Giuseppe Castaldo, Andrea Bianco

Erschienen in: Lung | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Despite the unprecedented effort of the scientific community, the novel SARS-CoV-2 virus has infected more than 46 million people worldwide, killing over one million two hundred thousand. Understanding the mechanisms by which some individuals are more susceptible to SARS-CoV-2 infection and why a subgroup of them are prone to experience severe pneumonia, and death should lead to a better approach and more effective treatments for COVID-19. Here, we focus our attention on ACE2, a primary receptor of SARS-CoV-2. We will discuss its biology, tissue expression, and post-translational regulation that determine its potential to be employed by SARS-CoV-2 for cell entry. Particular attention will be given to how the ACE2 soluble form can have a great impact on disease progression and thus be used in a potential therapeutic strategy. Furthermore, we will discuss repercussions that SARS-CoV-2/ACE2 binding has on the renin–angiotensin system and beyond. Indeed, although mostly neglected, ACE2 can also act on [des-Arg 937]-bradykinin of the kinin–kallikrein system regulating coagulation and inflammation. Thorough comprehension of the role that ACE2 plays in different pathways will be the key to assess the impact that SARS-CoV-2/ACE2 binding has on organismal physiology and will help us to find better therapies and diagnostic tools.

Cui J, Li F, Shi ZL (2019) Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17(3):181–192. https://doi.org/10.1038/s41579-018-0118-9CrossRefPubMed

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733. https://doi.org/10.1056/NEJMoa2001017CrossRefPubMedPubMedCentral

Samavati L, Uhal BD (2020) ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol 10:317. https://doi.org/10.3389/fcimb.2020.00317CrossRefPubMedPubMedCentral

Batlle D, Wysocki J, Satchell K (2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 134(5):543–545. https://doi.org/10.1042/CS20200163CrossRef

Mathewson AC, Bishop A, Yao Y, Kemp F, Ren J, Chen H, Xu X, Berkhout B, van der Hoek L, Jones IM (2008) Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2. J Gen Virol 89(Pt 11):2741–2745. https://doi.org/10.1099/vir.0.2008/003962-0CrossRefPubMedPubMedCentral

Letko M, Marzi A, Munster V (2020) Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 5(4):562–569. https://doi.org/10.1038/s41564-020-0688-yCrossRefPubMed

Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W, Campanero-Rhodes MA, Zhang Y, Eickmann M, Kiso M, Hay A, Matrosovich M, Feizi T (2009) Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol 27(9):797–799. https://doi.org/10.1038/nbt0909-797CrossRefPubMedPubMedCentral

Bianco A, Whiteman SC, Sethi SK, Allen JT, Knight RA, Spiteri MA (2000) Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial cells of atopic subjects: a mechanism for increased rhinovirus infection? Clin Exp Immunol 121(2):339–345. https://doi.org/10.1046/j.1365-2249.2000.01301.xCrossRefPubMedPubMedCentral

Sethi SK, Bianco A, Allen JT, Knight RA, Spiteri MA (1997) Interferon-gamma (IFN-gamma) down-regulates the rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) on human airway epithelial cells. Clin Exp Immunol 110(3):362–369. https://doi.org/10.1046/j.1365-2249.1997.4221440.xCrossRefPubMedPubMedCentral

10.

Whiteman SC, Bianco A, Knight RA, Spiteri MA (2003) Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem 278(14):11954–11961. https://doi.org/10.1074/jbc.M205329200CrossRefPubMed

11.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87(5):E1-9. https://doi.org/10.1161/01.res.87.5.e1CrossRefPubMed

12.

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275(43):33238–33243. https://doi.org/10.1074/jbc.M002615200CrossRefPubMed

13.

Devaux CA, Rolain JM, Raoult D (2020) ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect 53(3):425–435. https://doi.org/10.1016/j.jmii.2020.04.015CrossRefPubMedPubMedCentral

14.

Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23(4):177–183. https://doi.org/10.1016/s0165-6147(00)01994-5CrossRefPubMed

15.

Clarke NE, Belyaev ND, Lambert DW, Turner AJ (2014) Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin Sci (Lond) 126(7):507–516. https://doi.org/10.1042/CS20130291CrossRef

16.

Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, Kimura A, Ito H, Penninger JM, Imai Y, Kuba K (2013) Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 123(12):5203–5211. https://doi.org/10.1172/JCI69608CrossRefPubMedPubMedCentral

17.

Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T (2008) Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118(10):3343–3354. https://doi.org/10.1172/JCI34871.PMID:18769630CrossRefPubMedPubMedCentral

18.

Siddiquee K, Hampton J, McAnally D, May L, Smith L (2013) The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 168(5):1104–1117. https://doi.org/10.1111/j.1476-5381.2012.02192.xCrossRefPubMedPubMedCentral

19.

Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ (2014) Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci (Lond) 127(4):243–249. https://doi.org/10.1042/CS20130420CrossRef

20.

Wang Y, Wang Y, Luo W, Huang L, Xiao J, Li F, Qin S, Song X, Wu Y, Zeng Q, Jin F, Wang Y (2020) A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int J Med Sci 17(11):1522–1531. https://doi.org/10.7150/ijms.46695CrossRefPubMedPubMedCentral

21.

Zou X, Chen K, Zou J, Han P, Hao J, Han Z (2020) Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 14(2):185–192. https://doi.org/10.1007/s11684-020-0754-0CrossRefPubMed

22.

Serfozo P, Wysocki J, Gulua G, Schulze A, Ye M, Liu P, Jin J, Bader M, Myöhänen T, García-Horsman JA, Batlle D (2020) Ang II (angiotensin II) conversion to angiotensin-(1–7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75(1):173–182. https://doi.org/10.1161/HYPERTENSIONAHA.119.14071CrossRefPubMed

23.

Zhuang MW, Cheng Y, Zhang J, Jiang XM, Wang L, Deng J, Wang PH (2020) Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection. J Med Virol. https://doi.org/10.1002/jmv.26139CrossRefPubMedPubMedCentral

24.

Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH II, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J, HCA Lung Biological Network (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(5):1016–1035. https://doi.org/10.1016/j.cell.2020.04.035CrossRefPubMedPubMedCentral

25.

Onabajo OO, Banday AR, Stanifer ML, Yan W, Obajemu A, Santer DM, Florez-Vargas O, Piontkivska H, Vargas JM, Ring TJ, Kee C, Doldan P, Tyrrell DL, Mendoza JL, Boulant S, Prokunina-Olsson L (2020) Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Nat Genet. https://doi.org/10.1038/s41588-020-00731-9CrossRefPubMed

26.

Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D (2004) Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43(5):1120–1125. https://doi.org/10.1161/01.HYP.0000126192.27644.76CrossRefPubMed

27.

Cholankeril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer SP, Kim D, Hsing A, Ahmed A (2020) High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome Coronavirus 2: early experience from California. Gastroenterology 159(2):775–777. https://doi.org/10.1053/j.gastro.2020.04.008CrossRefPubMed

28.

Werion A, Belkhir L, Perrot M, Schmit G, Aydin S, Chen Z, Penaloza A, De Greef J, Yildiz H, Pothen L, Yombi JC, Dewulf J, Scohy A, Gérard L, Wittebole X, Laterre PF, Miller SE, Devuyst O, Jadoul M, Morelle J, Cliniques universitaires Saint-Luc (CUSL) COVID-19 Research Group (2020) SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int 98(5):1296–1307CrossRefPubMedPubMedCentral

29.

Boccia M, Aronne L, Celia B, Mazzeo G, Ceparano M, D’Agnano V, Parrella R, Valente T, Bianco A, Perrotta F (2020) COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis. https://doi.org/10.4081/monaldi.2020.1300CrossRefPubMed

30.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277(17):14838–14843. https://doi.org/10.1074/jbc.M200581200CrossRefPubMed

31.

Jacobs M, Van Eeckhoutte HP, Wijnant SRA, Janssens W, Joos GF, Brusselle GG, Bracke KR (2020) Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur Respir J 56(2):2002378. https://doi.org/10.1183/13993003.02378-2020CrossRefPubMedPubMedCentral

32.

Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR, Sin DD (2020) ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 55(5):2000688. https://doi.org/10.1183/13993003.00688-2020CrossRefPubMedPubMedCentral

33.

Smith JC, Sausville EL, Girish V, Yuan ML, Vasudevan A, John KM, Sheltzer JM (2020) Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract. Dev Cell 53(5):514-529.e3. https://doi.org/10.1016/j.devcel.2020.05.012CrossRefPubMedPubMedCentral

34.

Rossato M, Russo L, Mazzocut S, Di Vincenzo A, Fioretto P, Vettor R (2020) Current smoking is not associated with COVID-19. Eur Respir J 55(6):2001290. https://doi.org/10.1183/13993003.01290-2020CrossRefPubMedPubMedCentral

35.

Lee IT, Nakayama T, Wu CT, Goltsev Y, Jiang S, Gall PA, Liao CK, Shih LC, Schürch CM, McIlwain DR, Chu P, Borchard NA, Zarabanda D, Dholakia SS, Yang A, Kim D, Chen H, Kanie T, Lin CD, Tsai MH, Phillips KM, Kim R, Overdevest JB, Tyler MA, Yan CH, Lin CF, Lin YT, Bau DT, Tsay GJ, Patel ZM, Tsou YA, Tzankov A, Matter MS, Tai CJ, Yeh TH, Hwang PH, Nolan GP, Nayak JV, Jackson PK (2020) ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs. Nat Commun 11(1):5453. https://doi.org/10.1038/s41467-020-19145-6CrossRefPubMedPubMedCentral

36.

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821):430–436. https://doi.org/10.1038/s41586-020-2521-4CrossRefPubMedPubMedCentral

37.

Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, Ohnishi H, Yoshida H, Takizawa H, Saitoh S, Ura N, Shimamoto K, Miura T (2015) Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 28(1):15–21. https://doi.org/10.1093/ajh/hpu086CrossRefPubMed

38.

Kimura H, Francisco D, Conway M, Martinez FD, Vercelli D, Polverino F, Billheimer D, Kraft M (2020) Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 146(1):80–88. https://doi.org/10.1016/j.jaci.2020.05.004CrossRefPubMedPubMedCentral

39.

Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, Visness CM, Durham SR, Larson D, Esnault S, Ober C, Gergen PJ, Becker P, Togias A, Gern JE, Altman MC (2020) Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 146(1):203–206. https://doi.org/10.1016/j.jaci.2020.04.009CrossRefPubMedPubMedCentral

40.

Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV (2020) COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 202(1):83–90. https://doi.org/10.1164/rccm.202003-0821OCCrossRefPubMedPubMedCentral

41.

Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88(2):1293–1307. https://doi.org/10.1128/JVI.02202-13CrossRefPubMedPubMedCentral

42.

Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280(34):30113–30119. https://doi.org/10.1074/jbc.M505111200CrossRefPubMed

43.

Haga S, Nagata N, Okamura T, Yamamoto N, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y (2010) TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res 85(3):551–555. https://doi.org/10.1016/j.antiviral.2009.12.001CrossRefPubMed

44.

Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y (2008) Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci USA 105(22):7809–7814. https://doi.org/10.1073/pnas.0711241105CrossRefPubMedPubMedCentral

45.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271–280. https://doi.org/10.1016/j.cell.2020.02.052CrossRefPubMedPubMedCentral

46.

Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T (2011) A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 85(2):873–882. https://doi.org/10.1128/JVI.02062-10CrossRefPubMed

47.

Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB Jr (2009) Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 297(1):L84–L96. https://doi.org/10.1152/ajplung.00071.2009CrossRefPubMedPubMedCentral

48.

Ramchand J, Patel SK, Kearney LG, Matalanis G, Farouque O, Srivastava PM, Burrell LM (2020) Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis. JACC Cardiovasc Imaging 13(3):655–664. https://doi.org/10.1016/j.jcmg.2019.09.005CrossRefPubMed

49.

Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52(9):750–754. https://doi.org/10.1016/j.jacc.2008.02.088CrossRefPubMedPubMedCentral

50.

Lambert DW, Clarke NE, Hooper NM, Turner AJ (2008) Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 582(2):385–390. https://doi.org/10.1016/j.febslet.2007.11.085CrossRefPubMed

51.

Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24(8):1634–1643. https://doi.org/10.1038/sj.emboj.7600640CrossRefPubMedPubMedCentral

52.

Li Q, Cao Z, Rahman P (2020) Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. Mol Genet Genomic Med 8(8):e1344. https://doi.org/10.1002/mgg3.1344CrossRefPubMedPubMedCentral

53.

Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, Doddato G, Giliberti A, Marconi C, Musacchia F, Pippucci T, Torella A, Trezza A, Valentino F, Baldassarri M, Brusco A, Asselta R, Bruttini M, Furini S, Seri M, Nigro V, Matullo G, Tartaglia M, Mari F, GEN-COVID Multicenter Study, Renieri A, Pinto AM (2020) ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur J Hum Genet 28(11):1602–1614CrossRefPubMedPubMedCentral

54.

Guo X, Chen Z, Xia Y, Lin W, Li H (2020) Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2). J Transl Med 18(1):321. https://doi.org/10.1186/s12967-020-02486-7CrossRefPubMedPubMedCentral

55.

Rehman SU, Tabish M (2020) Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs. Clin Sci (Lond) 134(10):1143–1150. https://doi.org/10.1042/CS20200419CrossRef

56.

Irham LM, Chou WH, Calkins MJ, Adikusuma W, Hsieh SL, Chang WC (2020) Genetic variants that influence SARS-CoV-2 receptor TMPRSS2 expression among population cohorts from multiple continents. Biochem Biophys Res Commun 529(2):263–269. https://doi.org/10.1016/j.bbrc.2020.05.179CrossRefPubMedPubMedCentral

57.

Ciaglia E, Vecchione C, Puca AA (2020) COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr 8:206. https://doi.org/10.3389/fped.2020.00206CrossRefPubMedPubMedCentral

58.

Kornilov SA, Lucas I, Jade K, Dai CL, Lovejoy JC, Magis AT (2020) Plasma levels of soluble ACE2 are associated with sex, metabolic syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Crit Care 24(1):452. https://doi.org/10.1186/s13054-020-03141-9CrossRefPubMedPubMedCentral

59.

Swärd P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK (2020) Age and sex differences in soluble ACE2 may give insights for COVID-19. Crit Care 24(1):221. https://doi.org/10.1186/s13054-020-02942-2CrossRefPubMedPubMedCentral

60.

Lumpuy-Castillo J, Lorenzo-Almorós A, Pello-Lázaro AM, Sánchez-Ferrer C, Egido J, Tuñón J, Peiró C, Lorenzo Ó (2020) Cardiovascular damage in COVID-19: therapeutic approaches targeting the renin-angiotensin-aldosterone system. Int J Mol Sci 21(18):6471. https://doi.org/10.3390/ijms21186471CrossRefPubMedCentral

61.

Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Muench MO, Simmons G, Hofmann H, Kuri T, Weber F, Eichler J, Drosten C, Pöhlmann S (2010) Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol 84(2):1198–1205. https://doi.org/10.1128/JVI.01248-09CrossRefPubMed

62.

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112–116. https://doi.org/10.1038/nature03712CrossRefPubMedPubMedCentral

63.

Papp M, Li X, Zhuang J, Wang R, Uhal BD (2002) Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 282(4):L713–L718. https://doi.org/10.1152/ajplung.00103.2001CrossRefPubMed

64.

Welch WJ (2008) Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension 52(1):51–56. https://doi.org/10.1161/HYPERTENSIONAHA.107.090472CrossRefPubMed

65.

Dikalova A, Clempus R, Lassègue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK (2005) Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112(17):2668–2676. https://doi.org/10.1161/CIRCULATIONAHA.105.538934CrossRefPubMed

66.

Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE (2008) AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 120(3):292–316. https://doi.org/10.1016/j.pharmthera.2008.08.009CrossRefPubMedPubMedCentral

67.

Marchesi C, Paradis P, Schiffrin EL (2008) Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 29(7):367–374. https://doi.org/10.1016/j.tips.2008.05.003CrossRefPubMed

68.

Hrenak J, Paulis L, Simko F (2016) Angiotensin A/Alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 17(7):1098. https://doi.org/10.3390/ijms17071098CrossRefPubMedCentral

69.

Schmaier AH (2002) The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 109(8):1007–1009. https://doi.org/10.1172/JCI15490CrossRefPubMedPubMedCentral

70.

Kashuba E, Bailey J, Allsup D, Cawkwell L (2013) The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers. Biomarkers 18(4):279–296. https://doi.org/10.3109/1354750X.2013.787544CrossRefPubMed

71.

Su JB (2014) Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems. J Renin Angiotensin Aldosterone Syst 15(4):319–328. https://doi.org/10.1177/1470320312474854CrossRefPubMed

72.

Rahman AM, Murrow JR, Ozkor MA, Kavtaradze N, Lin J, De Staercke C, Hooper WC, Manatunga A, Hayek S, Quyyumi AA (2014) Endothelium-derived hyperpolarizing factor mediates bradykinin-stimulated tissue plasminogen activator release in humans. J Vasc Res 51(3):200–208. https://doi.org/10.1159/000362666CrossRefPubMed

73.

Qadri F, Bader M (2018) Kinin B1 receptors as a therapeutic target for inflammation. Expert Opin Ther Targets 22(1):31–44. https://doi.org/10.1080/14728222.2018.1409724CrossRefPubMed

74.

Murugesan P, Jung B, Lee D, Khang G, Doods H, Wu D (2016) Kinin B1 receptor inhibition with BI113823 reduces inflammatory response, mitigates organ injury, and improves survival among rats with severe sepsis. J Infect Dis 213(4):532–540. https://doi.org/10.1093/infdis/jiv426CrossRefPubMed

75.

Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, Prindle T, Fulton WB, Wang S, McCray PB Jr, Chappell M, Hackam DJ, Jia H (2018) Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg⁹ bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol 314(1):L17–L31. https://doi.org/10.1152/ajplung.00498.2016CrossRefPubMed

76.

van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Brüggemann RJ, van der Hoeven H (2020) Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife 9:e57555. https://doi.org/10.7554/eLife.57555CrossRefPubMedPubMedCentral

77.

Ingraham NE, Barakat AG, Reilkoff R, Bezdicek T, Schacker T, Chipman JG, Tignanelli CJ, Puskarich MA (2020) Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review. Eur Respir J 56(1):2000912. https://doi.org/10.1183/13993003.00912-2020CrossRefPubMedPubMedCentral

78.

Warner FJ, Smith AI, Hooper NM, Turner AJ (2004) Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell Mol Life Sci 61(21):2704–2713. https://doi.org/10.1007/s00018-004-4240-7CrossRefPubMedPubMedCentral

79.

Gouda AS, Mégarbane B (2020) Snake venom-derived bradykinin-potentiating peptides: a promising therapy for COVID-19? Drug Dev Res. https://doi.org/10.1002/ddr.21732CrossRefPubMedPubMedCentral

80.

Davidson AM, Wysocki J, Batlle D (2020) Interaction of SARS-CoV-2 and other Coronavirus with ACE (Angiotensin-Converting Enzyme)-2 as their main receptor: therapeutic implications. Hypertension 76(5):1339–1349. https://doi.org/10.1161/HYPERTENSIONAHA.120.15256CrossRefPubMed

81.

Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S (2013) Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52(9):783–792. https://doi.org/10.1007/s40262-013-0072-7CrossRefPubMed

82.

Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL (2017) A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care 21(1):234. https://doi.org/10.1186/s13054-017-1823-xCrossRefPubMedPubMedCentral

83.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905–913. https://doi.org/10.1016/j.cell.2020.04.004CrossRefPubMedPubMedCentral

84.

Inal JM (2020) Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy. Clin Sci (Lond) 34(12):1301–1304. https://doi.org/10.1042/CS20200623CrossRef

85.

Kruse RL (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9:72. https://doi.org/10.12688/f1000research.22211.2CrossRefPubMedPubMedCentral

86.

Saeedi Saravi SS, Beer JH (2020) Apelin-potential therapy for COVID-19? J Mol Cell Cardiol 145:84–87. https://doi.org/10.1016/j.yjmcc.2020.06.007CrossRefPubMedPubMedCentral

87.

Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D’Agnano V, Komici K, Mazzarella G, Parrella R, Bianco A (2020) COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res 32(8):1599–1608. https://doi.org/10.1007/s40520-020-01631-yCrossRefPubMedPubMedCentral

88.

Perrotta F, Matera MG, Cazzola M, Bianco A (2020) Severe respiratory SARS-CoV2 infection: does ACE2 receptor matter? Respir Med 168:105996. https://doi.org/10.1016/j.rmed.2020.105996CrossRefPubMedPubMedCentral

Titel: ACE2: The Major Cell Entry Receptor for SARS-CoV-2
verfasst von: Filippo Scialo
Aurora Daniele
Felice Amato
Lucio Pastore
Maria Gabriella Matera
Mario Cazzola
Giuseppe Castaldo
Andrea Bianco
Publikationsdatum: 10.11.2020
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Lung / Ausgabe 6/2020
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-020-00408-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

ACE2: The Major Cell Entry Receptor for SARS-CoV-2

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

Update 2020: Management of Non-Small Cell Lung Cancer

Association of Xpert MTB/RIF Cycle Threshold Values with Tuberculosis Treatment Outcomes

Obstructive Sleep Apnea Severity, Body Mass Index, and Circulating Levels of Cellular Adhesion Molecules

Postoperative Adverse Events are Associated with Oncologic Recurrence Following Curative-intent Resection for Lung Cancer

The Integrin Inhibitor Cilengitide and Bleomycin-Induced Pulmonary Fibrosis

Is There (Will There Be) a Post-COVID-19 Chronic Cough?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin